Abstract YO40
Case summary
Introduction: Giant cell tumor (GCT) of bone are benign but locally aggressive primary bone tumors.They occur predominantly in long bones of adolescents and young adults typically in the epiphysis. Malignant giant cell tumors of bone (MGCTB) are rare, occurring in less than 1% of GCT of bone. Primary malignant GCT (PMGCT) is a high-grade sarcoma that arises side by side with benign GCTs. Secondary malignant GCT (SMGCT) is a high-grade sarcoma that occurs at the site where a GCTwas previously treated either by radiotherapy (radiation-induced form) or surgery (evolutionary form).
Case Description: A 30 year old female presented with progressive swelling and pain around the left knee for six months without any significant preceding history. X- Ray showed an expansile lytic lesion involving epiphysis of tibia and features suggestive of GCT. She underwent tumor resection and custom made prosthesis replacement. Post op histopathology showedGCT.Six months later the pain and swelling recurred. She was re evaluated with CT left leg which showed recurrent GCT 20x20 cm with soft tissue extension.Biopsy showed malignancy with GCT.Whole body FDG-PET CT was suggestive of tumor recurrence in left proximal tibia with associated soft tissue mass with inguinal nodal and pulmonary metastasis. She received palliative RT 30Gy in 10 fractions.Due to local progression she underwent palliative above knee amputation. Post op histopathology was suggestive of giant cell rich sarcoma.She received 3 cycles of chemotherapy with cisplatin and adriamycin. She expired after 3rd cycle of chemotherapy.
Discussion:PMGCT typically is difficult to distinguish from giant cell tumor of bone, as clinical and radiographic presentation of PMGCT can mimic that of a benign lesion. Malignancies in GCTs are extremely rare events. Since these are aggressive tumors with poor prognosis, it is important that they be recognized at an early stage so that they can be treated adequately by aggressive surgery and chemotherapy.
Clinical trial identification
Editorial acknowledgement
Resources from the same session
27P - The prognostic value of neutrophil to lymphocyte ratio (NLR) and 18F-FDG PET SUV in breast cancer patients underwent neoadjuvant chemotherapy
Presenter: Soong June Bae
Session: Poster display session
Resources:
Abstract
28P - Accuracy of core biopsy in predicting pathologic complete response in the breast in patients with complete/near complete clinical and radiological response (Complete Responders in the Breast – CRBr): A feasibility study
Presenter: Nisha Hariharan
Session: Poster display session
Resources:
Abstract
29P - Tumour response to neoadjuvant chemotherapy in breast cancer: Routine pathologic markers improve the predictive power of a cell-loss metric based on release of thymidine kinase 1 into blood
Presenter: Bernhard Tribukait
Session: Poster display session
Resources:
Abstract
30P - Comparison of metabolic changes between neoadjuvant chemotherapy and neoadjuvant endocrine therapy in premenopausal women with ER positive, HER2 negative breast cancer
Presenter: Ho-hyun Ryu
Session: Poster display session
Resources:
Abstract
31P - Circulating miR-155 as a potential therapeutic monitoring marker in breast cancer
Presenter: Sumadi Lukman Anwar
Session: Poster display session
Resources:
Abstract
32P - Profile of breast cancer epidemiology in Sanglah General Hospital, Denpasar, Bali from 2012 to 2019
Presenter: Citra Aryanti
Session: Poster display session
Resources:
Abstract
33P - Contrast enhanced chest CT in patients with breast cancer: Comprehensive imaging analysis and correlation with biological markers
Presenter: Bo Hwa Choi
Session: Poster display session
Resources:
Abstract
34P - Verification of metabolic regulatory mechanisms in androgen receptor-positive triple negative breast cancer
Presenter: Yuka Asano
Session: Poster display session
Resources:
Abstract
35TiP - Ribociclib plus goserelin with hormonal therapy versus physician choice chemotherapy in pre-/perimenopausal patients with HR+, HER2– inoperable locally advanced breast cancer (ABC): RIGHT choice study
Presenter: Yen-Shen Lu
Session: Poster display session
Resources:
Abstract
36TiP - A prospective study to assess response to neoadjuvant hormonal therapy in postmenopausal women with hormone-receptor positive breast cancer at a regional cancer centre in South India
Presenter: Shina Goyal
Session: Poster display session
Resources:
Abstract